Ralph Weichselbaum to Fluorouracil
This is a "connection" page, showing publications Ralph Weichselbaum has written about Fluorouracil.
Connection Strength
0.909
-
Intensified concomitant chemoradiotherapy with and without filgrastim for poor-prognosis head and neck cancer. J Clin Oncol. 1994 Nov; 12(11):2351-9.
Score: 0.095
-
Hydroxyurea with concomitant radiotherapy for locally advanced head and neck cancer. Semin Oncol. 1992 Jun; 19(3 Suppl 9):53-8.
Score: 0.080
-
The interaction of 5-fluorouracil, hydroxyurea, and radiation in two human head and neck cancer cell lines. Oncology. 1992; 49(6):454-60.
Score: 0.078
-
Hydroxyurea, fluorouracil, and concomitant radiotherapy in poor-prognosis head and neck cancer: a phase I-II study. J Clin Oncol. 1989 Jun; 7(6):761-8.
Score: 0.065
-
Integrated Clinical-Molecular Classification of Colorectal Liver Metastases: A Biomarker Analysis of the Phase 3 New EPOC Randomized Clinical Trial. JAMA Oncol. 2023 09 01; 9(9):1245-1254.
Score: 0.044
-
Concomitant chemoradiotherapy as primary therapy for locoregionally advanced head and neck cancer. J Clin Oncol. 2000 Apr; 18(8):1652-61.
Score: 0.035
-
Paclitaxel, 5-fluorouracil, hydroxyurea, and concomitant radiation therapy for poor-prognosis head and neck cancer. Semin Radiat Oncol. 1999 Apr; 9(2 Suppl 1):70-6.
Score: 0.032
-
Pharmacodynamics of fluorouracil-based induction chemotherapy in advanced head and neck cancer. J Clin Oncol. 1996 May; 14(5):1663-71.
Score: 0.026
-
The role of paclitaxel in the treatment of head and neck cancer. Semin Oncol. 1995 Oct; 22(5 Suppl 12):8-12.
Score: 0.025
-
Hydroxyurea with continuous infusion paclitaxel, 5-fluorouracil, and concomitant radiotherapy for poor-prognosis head and neck cancer. Semin Oncol. 1995 Jun; 22(3 Suppl 6):47-52.
Score: 0.025
-
Patterns of failure of complete responders following high-dose chemotherapy and autologous bone marrow transplantation for metastatic breast cancer: implications for the use of adjuvant radiation therapy. Int J Radiat Oncol Biol Phys. 1994 Aug 30; 30(1):151-60.
Score: 0.023
-
Comparison of carboplatin-paclitaxel to docetaxel-cisplatin-5-flurouracil induction chemotherapy followed by concurrent chemoradiation for locally advanced head and neck cancer. Oral Oncol. 2014 Jan; 50(1):52-8.
Score: 0.022
-
A phase I dose escalation study of Ad GV.EGR.TNF.11D (TNFerade⢠Biologic) with concurrent chemoradiotherapy in patients with recurrent head and neck cancer undergoing reirradiation. Ann Oncol. 2013 Mar; 24(3):769-76.
Score: 0.021
-
Concomitant chemoradiotherapy with cisplatin, 5-fluorouracil and hydroxyurea in poor-prognosis head and neck cancer. Laryngoscope. 1992 Jun; 102(6):630-6.
Score: 0.020
-
Neoadjuvant PFL augmented by methotrexate and piritrexim followed by concomitant chemoradiotherapy for advanced head and neck cancer: a feasible and active approach. Ann Oncol. 1992 Jan; 3(1):79-81.
Score: 0.020
-
5-Fluorouracil, leucovorin, hydroxyurea, and escalating doses of continuous-infusion cisplatin with concomitant radiotherapy: a clinical and pharmacologic study. Cancer Chemother Pharmacol. 1992; 29(3):178-84.
Score: 0.020
-
Survival and analysis of failure following hydroxyurea, 5-fluorouracil and concomitant radiation therapy in poor prognosis head and neck cancer. Am J Clin Oncol. 1991 Oct; 14(5):419-26.
Score: 0.019
-
Cisplatin and fluorouracil chemotherapy does not yield long-term benefit in locally advanced head and neck cancer: results from a single institution. J Clin Oncol. 1991 Aug; 9(8):1376-84.
Score: 0.019
-
Vascular events in patients receiving high-dose infusional 5-fluorouracil-based chemotherapy: the University of Chicago experience. Med Pediatr Oncol. 1991; 19(1):8-15.
Score: 0.018
-
A randomized study comparing two regimens of neoadjuvant and adjuvant chemotherapy in multimodal therapy for locally advanced head and neck cancer. Cancer. 1990 Jul 15; 66(2):206-13.
Score: 0.018
-
Induction chemotherapy with cisplatin, fluorouracil, and high-dose leucovorin for locally advanced head and neck cancer: a clinical and pharmacologic analysis. J Clin Oncol. 1990 Feb; 8(2):241-7.
Score: 0.017
-
Phase I study of bevacizumab added to fluorouracil- and hydroxyurea-based concomitant chemoradiotherapy for poor-prognosis head and neck cancer. J Clin Oncol. 2008 Apr 01; 26(10):1732-41.
Score: 0.015
-
Twice-daily reirradiation for recurrent and second primary head-and-neck cancer with gemcitabine, paclitaxel, and 5-fluorouracil chemotherapy. Int J Radiat Oncol Biol Phys. 2005 Mar 15; 61(4):1096-106.
Score: 0.012
-
Induction chemotherapy followed by concomitant TFHX chemoradiotherapy with reduced dose radiation in advanced head and neck cancer. Clin Cancer Res. 2003 Dec 01; 9(16 Pt 1):5936-43.
Score: 0.011
-
Multicenter randomized Phase II study of paclitaxel (1-hour infusion), fluorouracil, hydroxyurea, and concomitant twice daily radiation with or without erythropoietin for advanced head and neck cancer. Clin Cancer Res. 2003 May; 9(5):1689-97.
Score: 0.011
-
Induction chemotherapy followed by concomitant chemoradiotherapy in the treatment of locoregionally advanced nasopharyngeal cancer. Ann Oncol. 2003 Apr; 14(4):564-9.
Score: 0.011
-
Weekly carboplatin and paclitaxel followed by concomitant paclitaxel, fluorouracil, and hydroxyurea chemoradiotherapy: curative and organ-preserving therapy for advanced head and neck cancer. J Clin Oncol. 2003 Jan 15; 21(2):320-6.
Score: 0.010
-
Concomitant infusional paclitaxel and fluorouracil, oral hydroxyurea, and hyperfractionated radiation for locally advanced squamous head and neck cancer. J Clin Oncol. 2001 Apr 01; 19(7):1961-9.
Score: 0.009
-
Induction chemotherapy followed by concomitant chemoradiotherapy in the treatment of locoregionally advanced oropharyngeal cancer. Cancer J. 2001 Mar-Apr; 7(2):140-8.
Score: 0.009
-
Multimodality therapy in advanced paranasal sinus carcinoma: superior long-term results. Cancer J Sci Am. 1999 Jul-Aug; 5(4):219-23.
Score: 0.008
-
Radiation therapy with concomitant hydroxyurea and fluorouracil in stage II and III head and neck cancer. J Clin Oncol. 1999 Feb; 17(2):638-44.
Score: 0.008
-
Induction chemotherapy followed by concurrent chemoradiation for advanced head and neck cancer: improved disease control and survival. J Clin Oncol. 1998 Aug; 16(8):2715-21.
Score: 0.008
-
Phase I study of concomitant chemoradiotherapy with paclitaxel, fluorouracil, and hydroxyurea with granulocyte colony-stimulating factor support for patients with poor-prognosis cancer of the head and neck. J Clin Oncol. 1998 Feb; 16(2):735-44.
Score: 0.007
-
Thymidylate synthase expression and response to neoadjuvant chemotherapy in patients with advanced head and neck cancer. J Natl Cancer Inst. 1997 Feb 19; 89(4):308-13.
Score: 0.007
-
Continuous infusion paclitaxel, 5-fluorouracil, and hydroxyurea with concomitant radiotherapy in patients with advanced or recurrent head and neck cancer. Semin Oncol. 1997 Feb; 24(1 Suppl 2):S2-68-S2-71.
Score: 0.007
-
Re-irradiation with concomitant chemotherapy of unresectable recurrent head and neck cancer: a potentially curable disease. Ann Oncol. 1996 Nov; 7(9):913-8.
Score: 0.007
-
Time-dose relationship for local tumor control following alternate week concomitant radiation and chemotherapy of advanced head and neck cancer. Int J Radiat Oncol Biol Phys. 1994 Apr 30; 29(1):153-62.
Score: 0.006
-
Locoregionally advanced paranasal sinus carcinoma. Favorable survival with multimodality therapy. Arch Otolaryngol Head Neck Surg. 1993 Jul; 119(7):743-6.
Score: 0.005
-
Cisplatin, fluorouracil, and leucovorin augmented by interferon alfa-2b in head and neck cancer: a clinical and pharmacologic analysis. J Clin Oncol. 1993 Feb; 11(2):360-8.
Score: 0.005
-
Favorable long-term survival following induction chemotherapy with cisplatin, fluorouracil, and leucovorin and concomitant chemoradiotherapy for locally advanced head and neck cancer. J Natl Cancer Inst. 1992 Jun 03; 84(11):877-82.
Score: 0.005
-
Neoadjuvant and adjuvant methotrexate, cisplatin, and fluorouracil in multimodal therapy of head and neck cancer. J Clin Oncol. 1989 Jul; 7(7):838-45.
Score: 0.004
-
Cisplatin, 5-fluorouracil, and high-dose oral leucovorin for advanced head and neck cancer. Cancer. 1989 Mar 15; 63(6 Suppl):1048-53.
Score: 0.004
-
A randomized study of inpatient versus outpatient continuous infusion chemotherapy for patients with locally advanced head and neck cancer. Cancer. 1989 Jan 01; 63(1):30-6.
Score: 0.004
-
Concomitant hydroxyurea, 5-fluorouracil, and radiation therapy for recurrent head and neck cancer: early results. Otolaryngol Head Neck Surg. 1988 Apr; 98(4):295-8.
Score: 0.004
-
Cisplatin, fluorouracil, and high-dose leucovorin for recurrent or metastatic head and neck cancer. J Clin Oncol. 1988 Apr; 6(4):618-26.
Score: 0.004
-
Sequential administration of methotrexate, cisplatin, and 5-fluorouracil in multimodal therapy for locally advanced head and neck cancer. NCI Monogr. 1988; (6):353-6.
Score: 0.004
-
Palliation of hepatic metastasis. Cancer. 1978 May; 41(5):2013-7.
Score: 0.002